Ranbaxy Of India Seeks To Rebuild Relations With U.S. FDA
This article was originally published in PharmAsia News
Executive SummaryIndia's Ranbaxy Laboratories says in its annual report it plans to rebuild its strained relationship with U.S. FDA. Malvinder Mohan Singh, CEO and managing director of Ranbaxy, wrote in the report the company's focus is to be on resolving FDA's issues of compliance and good manufacturing practices. The company has plans to acquire FDA-approved manufacturing facilities to produce drugs once made at a pair of plants the FDA blacklisted. (Click here for more
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.